Actinium Pharmaceuticals Appoints Xin Du as Executive Director, Regulatory Affairs and Srivastava as Associate Director of Project Management

Actinium Pharmaceuticals, Inc. announced the appointment of Dr. Xin Du, Ph.D., to the position of Executive Director, Regulatory Affairs and Dr. Sri Srivastava, Ph.D., PMP, to the position of Associate Director of Project Management. Dr. Srivastava will have operational responsibilities for Actinium's Actimab-A program including the planned Phase 2 trial, planning and process optimization, management of external vendors and the coordination of all clinical trial related matters. Dr. Du will be responsible for managing Actinium's regulatory submissions, CMC efforts, interacting with regulatory agencies and developing the Company's regulatory strategy as pertains to both Iomab-B, Actimab-A and all future programs. Both hires are especially timely given the planned transformation of Actinium into a later stage product development company in 2016.

Dr. Du said. Dr. Xin Du, Ph.D., is a senior regulatory professional with over 15 years of industry experience and a proven track record of product approvals, regulatory strategy and efficient regulatory submission management. Most recently, Dr. Du was Senior Director and Global Regulatory CMC Head at NPS Pharmaceuticals, where he was instrumental in receiving approval for the company's first BLA submission and in the successful launch of the Company's first product in Europe.

Dr. Srivastava spent a decade at ClinTech Research where he provided consulting services focused on clinical operations for emerging biopharmaceuticals including Aestus Therapeutics where he managed a randomized Phase 2 clinical trial.